Viridian Therapeutics, Inc. (VRDN)

19.56 +1.18 (+6.42%) USD  |  NASDAQ  |  Oct 15, 16:00
19.54 -0.02 (-0.10%) After-Hours: 20:00
More

Viridian Therapeutics Cash from Operations (TTM) : -333.82M for June 30, 2026

Cash from Operations (TTM) Chart

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -333.82M
March 31, 2026 -303.87M
December 31, 2025 -276.87M
September 30, 2025 -325.97M
June 30, 2025 -309.06M
March 31, 2025 -279.75M
December 31, 2024 -232.32M
September 30, 2024 -196.99M
June 30, 2024 -168.26M
March 31, 2024 -167.42M
December 31, 2023 -184.17M
September 30, 2023
June 30, 2023
March 31, 2023
December 31, 2022
September 30, 2022
June 30, 2022 -67.54M
March 31, 2022 -64.08M
December 31, 2021 -54.58M
September 30, 2021 -47.48M
June 30, 2021 -40.70M
March 31, 2021 -32.86M
December 31, 2020 -29.78M
Date Value
September 30, 2020 -28.15M
June 30, 2020 -32.32M
March 31, 2020 -32.71M
December 31, 2019 -36.06M
September 30, 2019 -36.42M
June 30, 2019 -33.96M
March 31, 2019 -31.29M
December 31, 2018 -26.84M
September 30, 2018 -25.91M
June 30, 2018 -24.77M
March 31, 2018 -27.34M
December 31, 2017 -28.17M
September 30, 2017 -24.21M
June 30, 2017 -25.79M
March 31, 2017 -20.72M
December 31, 2016 -14.76M
September 30, 2016 -12.77M
June 30, 2016 -7.833M
March 31, 2016 -8.011M
December 31, 2015 -6.898M
September 30, 2015 -6.596M
June 30, 2015 -5.123M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 4.293B
TG Therapeutics, Inc. 17.88M
Travere Therapeutics, Inc. 92.70M
ACADIA Pharmaceuticals, Inc. 160.32M
Alnylam Pharmaceuticals, Inc. 885.89M